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Human immunodeficiency virus type 1 (HIV-1) hardly replicates in Old World monkeys. 
Recently, a mutant HIV-1 clone, NL-DT5R, in which a small part of gag and the entire vif 
gene are replaced with SIVmac239-derived ones, was shown to be able to replicate in pigtail 
monkeys but not in rhesus monkeys (RM). In the present study, we found that a modified 
monkey-tropic HIV-1 (HIV-1mt), MN4-5S, acquired the ability to replicate efficiently in 
cynomolgus monkeys as compared with the NL-DT5R, while neither NL-DT5R nor MN4-5S 
replicated in RM cells. These results suggest that multiple determinants may be involved in 
the restriction of HIV-1 replication in macaques, depending on the species of macaques.  
The new HIV-1mt clone will be useful for studying molecular mechanisms by which 








Human immunodeficiency virus type 1 (HIV-1) productively infects only humans but not Old 
World monkeys (OWM) such as cynomolgus macaques (CM) or rhesus macaques (RM), 
whereas RM-derived simian immunodeficiency virus (SIVmac) can efficiently replicate in 
OWM. Because of this species barrier, alternative monkey models using SIVmac or 
simian/human immunodeficiency viruses (SHIV) have been used for AIDS research [1-4]. 
However, detailed analyses of molecular mechanisms of the pathogenesis of HIV-1 have been 
hampered by the lack of appropriate non-human primate models for HIV-1 infection.  
The mechanistic basis for the inability of HIV-1 to replicate in OWM cells has remained 
unclear. Recently, a number of intrinsic anti-HIV-1 cellular factors, including tripartite motif 
protein 5 (TRIM5), Cyclophilin A (CypA), apolipoprotein B mRNA-editing catalytic 
polypeptide (APOBEC3) family and Tetherin were discovered in OWM cells [5, 6]. TRIM5 
strongly suppresses HIV-1 replication, mainly by affecting the viral disassembly step, 
resulting in a decrease of reverse transcription products [7, 8]. CypA acts as a regulator 
promoting TRIM5-mediated restriction of HIV-1 [8]. APOBEC3 is also a major regulator of 
HIV-1 replication [9, 10]. APOBEC3 exerts its inhibitory effect mainly by inducing G to A 
hypermutation into the viral genome due to its cytidine deaminase activity, while 
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hypermutation-independent inhibitory activity at the stage of reverse transcription is also 
evident [11]. Tetherin, also referred to as a BST-2, was identified as an intrinsic antiviral 
factor that restricts the egress of HIV-1 by tethering virions to the host cell surface [12, 13]. 
Importantly, HIV-1 can counteract human APOBEC3 activity by utilizing the viral accessory 
protein Vif, whereas it cannot counteract OWM APOBEC3 [14]. Similarly, HIV-1 
counteracts human Tetherin activity by utilizing another viral accessory protein Vpu, whereas 
HIV-1 does not counteract OWM Tetherin activity [15]. 
In an attempt to generate a monkey tropic HIV-1 (HIV-1mt), Kamada et al. 
constructed an HIV-1 variant carrying minimal SIVmac-derived sequences to overcome the 
restriction factors [16]. The prototype HIV-1 clone NL-DT5R had a sequence encoding an 
SIVmac loop between alpha-helices 4 and 5 (L4/5) of CA and the entire vif gene, which 
relieved the inhibitory effects on viral replication by restriction factors CypA, TRIM5 and 
APOBEC3. NL-DT5R was able to replicate in pigtail monkeys (PM) in vivo as well as in 
vitro, as reported by Igarashi et al. [17]. Although NL-DT5R induced immune responses in 
infected animals, the virus did not establish persistent infection. 
 In the present study, we sought to adapt NL-DT5R to CM by performing 
long-term passage in CM-derived HSC-F cells. We successfully obtained a modified 
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HIV-1mt clone having several mutations. Additionally, we inserted an SIVmac loop between 
alpha helices 6 and 7 (L6/7) of CA [18]. The resultant clone named MN4-5S was found to 
replicate efficiently and to induce strong immune responses in infected CM, suggesting the 















2. Materials and methods 
 
2.1. Plasmid construction 
The HIV-1 derivatives were constructed on a background of an infectious molecular clone, 
NL4-3 [19]. NL-DT5R, a cloned virus containing SIVmac239 L4/5 and the entire vif gene, 
was reported previously by Kamada et al. [16]. In addition, NL-DT562, a virus having an 
R5-tropic SF162-derived env gene on a background of NL-DT5R, was used in this study [20]. 
After long passage of NL-DT5R and NL-DT562 in cynomolgus T cell line HSC-F [21], 
several mutations were appeared in both viral genomes, and then all of them were inserted 
into NL-DT5R by gene-engineering techniques. Consequently, a clone having 14 nucleotide 
substitutions in its genome was constructed and named MN4-5. Among these substitutions, 7 
were non-synonymous mutations. The structure of the clone is shown in Fig. 1. A part of L6/7 
of CA (aa residues 120-122; HNP) of MN4-5 was also replaced with the corresponding 
segment of SIVmac239 CA (aa residues 120-123; RQQN) by means of site-directed 
mutagenesis as described previously [18]. The resultant construct was designated MN4-5S. 
 
2.2. Cells and viruses 
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Human embryonic kidney cell line HEK293T was maintained in DMEM supplemented with 
10% fetal bovine serum, 100 units/ml of penicillin and 100 g/ml of streptomycin (Sigma). 
Monkey peripheral blood mononuclear cells (PBMCs) were separated with a standard Ficoll 
density gradient separation method and cultured in R-10 composed of RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 100 units/ml of penicillin and 100 g/ml of 
streptomycin (Sigma). The growth kinetics of each HIV-1 clone were examined in activated 
CD8
+
 cell-depleted PBMCs. Briefly, separated PBMCs were reacted with a PE-labeled 
anti-CD8 antibody and then treated with anti-PE magnetic beads. After washing, CD8
+
 
cell-depleted PBMCs were negatively separated by using MACS columns (Miltenyi Biotec). 
For stimulation, CD8
+
 cell-depleted PBMCs were first cultured in R-10 containing 1 g/ml of 
concanavalin A (Sigma) for 2 days followed by culture in R-10 supplemented with 100 U/ml 
IL-2 (Shionogi) for more 2 days. The cells were then infected with 100 ng of p24 of HIV-1 
and the culture supernatant was collected periodically. HSC-F, a cynomolgus monkey-derived 
CD4
+
 T cell line [21], was cultured in R-10. 
Virus stocks were prepared as follows: sub-confluent HEK293T cells were transfected with 
proviral DNA using Lipofectamine2000 reagent according to the manufacturer’s instructions. 
At 42 hours after transfection, culture supernatants were centrifuged, filtrated with a 0.45 m 
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filter, and aliquoted as virus stocks for in vitro experiments. For preparation of viral stocks for 
in vivo experiments, CD8
+
 cell-depleted PBMCs were infected with the HEK293T-derived 
stocks as described above. After washing, the cells were maintained for several days and the 
culture supernatants were collected and stored as described above. 
 
2.3. Reverse transcription (RT) assay 
Virion-associated RT activity was measured as described previously [22]. HSC-F cells 
(1x10
6
) were infected with equal amounts of viruses (1x107 RT units). Viral growth kinetics 
was determined by RT production in the culture supernatants. 
 
2.4. Animal experiments 
Healthy adult cynomolgus monkeys were used in this study. All animals were confirmed to be 
negative for simian retrovirus and were housed in individual isolators in a biosafety level 3 
facility and maintained according to the National Institute of Biomedical Innovation rules and 
guidelines for experimental animal welfare. Bleeding and viral inoculation were performed 
under ketamine hydrochloride anesthesia. Viral stocks for inoculation were inoculated into 






lymphocytes were evaluated as described below. 
 
2.5. Flow cytometry and immunophenotyping of peripheral blood lymphocytes 
Immunophenotyping of freshly isolated PBMCs was performed according to standard 





T cells were identified using monoclonal antibodies (mAbs) to 
CD3 (clone SP34-2, BD Pharmingen), CD4 (clone L200, BD Pharmingen) and CD8 (clone 
DK25, DAKO). Flow cytometric acquisition and analysis of samples was performed on at 
least 10,000 events collected by a flow cytometer driven by FACSDiVa software. 
 
2.6. Analysis of antiviral antibody response 
Plasma samples from infected animals were first heat-inactivated at 56C for 30 min. Then, 
100-fold diluted samples were reacted with commercially available anti-HIV-1 antibody 
detection strips (New LAV Blot I, Bio-Rad) according to the manufacture’s instructions.  
 
2.7. In vivo depletion of CD8
+
 lymphocytes 
Infected animals received an anti-CD8 mAb (cM-T807) as follows: 10 mg/kg (body weight) 
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inoculation subcutaneously at 42 days post infection (DPI), followed by 5 mg/kg inoculation 
intravenously at 45, 49, and 52 DPI. The cM-T807 mAb was provided by the NIH Nonhuman 
Primate Reagent Resource. To repeatedly confirm the depletion of CD8
+
 cells in the presence 
of cM-T807, an anti-CD8 mAb (clone DK25, DAKO) was used as reported previously [23]. 
 
2.8. Quantification of viral RNA 
Total RNA was collected from monkey plasma using a High Pure Viral RNA Kit (Roche 
Diagnostics) according to the manufacturer’s instructions. Viral RNA was quantified with a 
quantitative real-time PCR system using TaqMan One-Step RT-PCR Master Mix Reagents 
(Applied Biosystems). The primers and probe used in this study were as follows: Forward 
primer: HIVgag683 (+) (5’-CTCTCGACGCAGGACTCGGCTTGCT-3’); Reverse primer: 
HIVgag803 (-) (5’-GCTCTCGCACCCATCTCTCTCCTTCTAGCC-3’); Probe: HIVgag 
TaqMan 720R748 (FAM- GCAAGAGGCGAGRGGCGGCGACTGGTGAG-TAMRA). The 
quantification and data analysis were performed using the iQ5 Real-Time PCR Detection 






3.1. Growth properties of prototype HIV-1mt clone, NL-DT5R in macaques in vitro and in 
vivo  
We first examined the replication properties of prototype HIV-1mt NL-DT5R in CD8
+
 
cell-depleted PBMCs of CM and RM. NL-DT5R replicated in the cells of CM but not in those 
of RM (Fig. 2). We next examined the in vivo replication properties of NL-DT5R in CM. 
Viral stocks for inoculation were prepared with CD8
+
 cell-depleted CM PBMCs as described 
above. Then, two monkeys were infected with NL-DT5R intravenously and bled periodically. 
As shown in Fig. 3A, NL-DT5R established infection as indicated by detectable levels of 
plasma viremia and an anti-HIV-1 antibody response, although the viral level was marginal 
(about 1 x 10
3
 copies/ml) and disappeared at 4 weeks post infection. These results indicated 
that although CM appeared permissive for NL-DT5R as compared with RM, the mutations 
introduced in NL-DT5R were not still sufficient to overcome the restriction by host factor(s) 
of these macaques.  
 
3.2. MN4-5S showed improved replication capability in CM CD8
+
 cell-depleted PBMCs 
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In order to improve the replication capability of HIV-1mt in CM, we conducted long-term 
passage of NL-DT5R in HSC-F cells. Additionally, NL-DT562, having an R5-tropic env gene 
on a background of NL-DT5R, was also passaged long-term in HSC-F cells. We found that 
the passaging improved the growth of the viruses (data not shown), and then viral clones were 
obtained after the long-term passaging and sequenced. Ten nucleotide substitutions were 
indentified in the NL-DT5R-derived clone and 4 nucleotide substitutions (except for the env 
gene) in the NL-DT562-derived clone. These 14 nucleotide substitutions (7 of which were 
non-synonymous mutations) were assembled and introduced into NL-DT5R. The resultant 
clone was named MN4-5, and its structure is shown in Fig. 1. We previously found that 
insertion of an SIVmac loop between alpha helices 6 and 7 (L6/7) of CA into the 
corresponding region in HIV-1 significantly enhanced the viral replication in HSC-F cells and 
PBMCs of CM by relieving the inhibitory effect of TRIM5 [18]. We therefore inserted an 
SIVmac-derived L6/7 sequence into MN4-5. The resultant clone was named MN4-5S (Fig. 1). 
In order to examine the impact of these modifications on the viral replication, we analyzed the 
replication properties of this “adapted” virus in HSC-F cells and CD8+ cell-depleted PBMCs 
of CM. MN4-5 showed higher replication as compared with NL-DT5R in both types of cells 
(Figs. 4 and 5). Moreover, MN4-5S showed enhanced growth capability in the cells as 
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compared with the parental clones, NL-DT5R and MN4-5 (Figs. 4 and 5).  
Notably, MN4-5S did not show any replication in RM cells (data not shown), 
indicating that the combination of the mutations introduced in NL-DT5R may be effective for 
escape from the restriction in CM cells but not in RM cells.  
 
3.3. MN4-5S induced greater viremia in CM as compared with parental clone, NL-DT5R 
Since MN4-5S showed enhanced ability to replicate in CM cells, we next examined the viral 
replication in vivo. The stock of MN4-5S virus was inoculated into 3 CM. MN4-5S induced 
10-fold higher viremia in infected animals at 2-3 weeks after infection (Fig. 6A), as compared 
with that induced by NL-DT5R (see Fig. 3). This result was consistent with the in vitro result 
(Fig. 5) and demonstrated that the mutations inserted into NL-DT5R contributed to 
enhancement of viral replication in vivo. In addition, at the acute phase of infection a slight 
decrease of CD4
+
 T cells was observed (Fig. 6B). The viremia became undetectable at 6 
weeks after infection. Thereafter, antibody response against MN4-5S was observed in infected 
animals (Fig. 6C). As indicated by comparison with the lane of the positive control as a 
standard, the degree of antibody response seemed to be stronger than that against NL-DT5R 
(see Fig. 3B and Fig. 6C). Next we attempted to clarify the role of CD8
+
 lymphocytes in the 
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disappearance of viremia. We conducted in vivo depletion of CD8
+
 cells by using a method 
reported previously [23]. We found that the reappearance of viremia was observed in all 
monkeys tested in parallel with the decline of CD8
+
 T cells after the anti-CD8 mAb 
administration (Fig. 6, A and D). This result indicated that CD8
+
 T cells had a critical role in 
















In the present study, we found that a modified HIV-1mt, MN4-5S, acquired greater 
ability to replicate in CM than NL-DT5R, and that both the SIVmac-derived L6/7 
(HNP120-122 > RQQN120-123 of CA) and a series of substitutions identified by long-term 
passage of NL-DT5R in HSC-F cells contributed to this ability (Fig.1). We recently showed 
that the substitution of L6/7 relieved the inhibitory effect of TRIM5 [18]. Additionally, our 
preliminary data suggest that non-synonymous mutations in the integrase and env genes are 
likely to be critical for the improved activity (Nomaguchi et al., manuscript in preparation). It 
is possible that these adaptive mutations may optimize the interaction between host and viral 
proteins.  
It seemed that the growth kinetics of NL-DT5R in PM were comparable with those 
of MN4-5S in CM, which had peak levels in acute viremia of approximately 10
4
 copies/ml 
[17]. It is therefore likely that PM may exhibit better susceptibility to HIV-1mt than CM. It is 
possible that the greater susceptibility of PM to HIV-1mt replication could be due to the 
genotype of TRIM5, because PM usually express a chimera between TRIM5 and CypA, 
so-called TRIM-Cyp, whose anti-HIV-1 activity is defective [24]. 
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One unexpected finding in this study was that MN4-5S was unable to replicate in 
PBMCs of RM (data not shown), which was in contrast with the greater susceptibility of RM 
to SIVmac infection. Our results suggested that RM was most resistant to HIV-1mt replication 
among the three macaque species. Since our HIV-1mt clones (NL-DT5R and MN4-5) were 
established on the basis of information obtained from serial passages of the viruses in 
CM-derived cells, it may be reasonable to consider that these viruses were consequently 
optimized to CM. Alternatively, it is also possible that anti-HIV-1 activities such as TRIM5 
and APOBEC3 of RM could be greater than those of other macaques. Further studies are in 
progress to address these questions.  
We demonstrated that the reappearance of viremia was observed in all monkeys 
tested in parallel with decline of CD8
+
 T cells after anti-CD8 mAb administration (Fig. 6, A 
and D). This result indicated that HIV-1-specific CD8
+
 T cells had a critical role in the control 
of HIV-1mt replication and suggested that the virus may be able to infect latently in vivo. In 
order to establish a set point viremia and persistent infection, further modifications of  
HIV-1mt may be required to enable potent escape from the antiviral immune response. 
Further mechanistic characterization of anti-HIV-1 restriction factors will help in 
the construction of highly replicative and pathogenic HIV-1mt clones. As in the case of SHIV, 
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in vivo passage of the virus could be a conventional and straightforward procedure for 
achieving such purposes [4]. However, the results of our study demonstrate that selective 
modification of HIV-1mt based on available knowledge regarding the molecular machineries 
is an alternative and powerful way. We are now in the process of developing the next 
generation of HIV-1mt that will acquire growth ability and pathogenicity in macaques as well 
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Legends of figures 
 
Fig. 1. Structure of HIV-1mt clones used in this study. The positions of nucleotide mutations 
are indicated by arrows in this figure. Among nucleotide substitutions, the positions of 
non-synonymous mutations are indicated in red. 
 
Fig. 2. Growth properties of the NL-DT5R in CD8
+
 cell-depleted PBMCs from CM (A) and 
RM (B). The cells were infected with NL-DT5R and the viral replication was monitored by 
p24 antigen in the culture supernatants using a p24 quantitative ELISA kit. Animal 
identifications are indicated at the top of each panel. 
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Fig. 3. Profiles of plasma viral RNA loads (A) and anti-HIV-1 antibody responses (B) in CM 
infected with NL-DT5R. Mf97-108 (open circles) and Mf97-070 (closed diamonds) were 
used in this study. Viral stocks for inoculation were prepared in CD8
+
 cell-depleted PBMCs, 
and then 6.1 ng p24 of HIV-1 were inoculated into each animal. Commercially available 
diagnostic HIV-1 Western blotting strips were reacted with 100-fold diluted monkey plasma. 
Plasma from HIV-1-infected or uninfected individuals was used as a positive or a negative 
control, respectively. 
 
Fig. 4. Growth properties of HIV-1mt in HSC-F cells. The cells were infected with a series of 
HIV-1mt derivatives. The viral replication was monitored by RT activity in the culture 
supernatants. 
 
Fig. 5. Growth properties of HIV-1mt in CD8
+
 cell-depleted PBMCs from four CM. The cells 
were infected with a series of HIV-1mt derivatives. The viral replication was monitored by 
p24 antigen in the culture supernatants using a p24 quantitative ELISA kit. Animal 
identifications are indicated at the top of each panel. 
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Fig. 6. Profiles of plasma viral RNA loads (A), circulating CD4
+
 T lymphocytes (B), 
anti-HIV-1 antibody responses (C) and circulating CD8
+
 T lymphocytes (D) in CM infected 
with HIV-1 derivatives. Viral stocks for inoculation were prepared in CD8
+
 cell-depleted 
PBMCs and then 10 ng of p24 of HIV-1 were inoculated into each animal. Commercially 
available diagnostic HIV-1 Western blotting strips were reacted with 100-fold diluted plasma 
of each monkey. Plasma from HIV-1 infected or uninfected individuals was used as a positive 
or negative control, respectively. The black arrow indicates the day of anti-CD8 mAb 
(cM-T807) inoculation. 







